In vitro analysis of two formulations of fluticasone/ salmeterol pMDI for delivered dose uniformity and aerodynamic particle size distributionSource: International Congress 2014 – Rationale behind respiratory drug development Year: 2014
Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 100s Year: 2007
Fine particle mass of salbutamol: diskus and turbuhaler in vitro compared Source: Eur Respir J 2002; 20: Suppl. 38, 499s Year: 2002
In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
In vitro fine particle characteristics of budesonide containing MDI and DPI products Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
In vitro comparison of output and particle size distribution of budesonide from metered-dose inhaler with three spacer devices during pediatric tidal breathingSource: Eur Respir J 2005; 26: Suppl. 49, 161s Year: 2005
Pharmacokinetic evaluation of two HFA pMDI formulations of salmeterol xinafoate administered through a spacer in healthy subjects Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
A submicron suspension of budesonide improves the mass of ICS delivered during early nebulization Source: Eur Respir J 2006; 28: Suppl. 50, 712s Year: 2006
Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to in vitro fine particle dose proportionality Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Efficiency of ipratropium bromide and salbutamol deposition in the lung delivered via a soft-spray inhaler or chlorofluorocarbon metered-dose inhaler Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Lung deposition and distribution of inhaled extra fine beclomethasone dipropionate / formoterol fumarate /glycopyrronium bromide (BDP/FF/GB) in subjects with and without airflow obstruction. Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021
Non-inferiority comparison of formoterol HFA (FM-HFA) pMDI with formoterol CFC (FM-CFC) pMDI in patients with symptomatic asthma Source: Eur Respir J 2007; 30: Suppl. 51, 358s Year: 2007
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Comparison of a new HFA 134a-formulated budesonide pMDI with a standard CFC-formulated budesonide pMDI in children with persistent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 160s Year: 2005
Assessment of the suitability of filters for use in clinical studies with an HFA fluticasone propionate pressurized metered dose inhaler (pMDI) and a valved holding chamber (VHC) Source: Annual Congress 2011 - Lung function today and tomorrow II Year: 2011
Performance of salmeterol/fluticasone propionate HFA MDIs with and without counter are comparable Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005
Safety of beclomethasone HFA (HFA BDP) pMDI compared with beclomethasone CFC pMDI (CFC BDP) over 12 weeks Source: Eur Respir J 2005; 26: Suppl. 49, 503s Year: 2005